Nursing Education for Remdesivir

- Antiviral
- Authorized for emergency use in the United States and administered intravenously by health care providers, as appropriate, to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. Severe disease is defined as patients with low blood oxygen levels or needing oxygen therapy or more intensive breathing support such as a mechanical ventilator.
- Ordering is restricted to Infectious Disease only
- Adult Administration:
    - Usual adult dose is 200mg on day 1 followed by 100mg daily for 4 days.
    - Administer as an IV infusion of 250mL over 120 minutes. Flush line with at least 30 mL NS after remdesivir infusion is complete
    - Pharmacy will mix medication with normal saline prior to administration.
- *****Important Information *****
    - Patient or designee must receive patient information prior to administration of the drug; Fact Sheet for Patients (Available in English and Spanish); To be printed directly from link in order.
    - Patient or designee must be aware that drug is not FDA approved and they may decline the use of the drug if they wish
    - Patient or designee must sign ***Informed Consent for Remdesivir.***
        - Specific consent can be printed directly from link in order. After consent has been signed, it will need to be scanned and uploaded into Epic.
        - Ordering provider (Infection Disease physician) will obtain and must sign the consent
        - *To eliminate touch points, verbal or telephone consent may be obtained and form may be signed outside of the patient room with 2 nurse's witness and signatures*
- Adverse Reactions:
    - Hepatic: Increased serum alanine aminotransferase (FDA 2020a), increased serum aspartate aminotransferase (FDA 2020a)
    - Miscellaneous: Infusion related reaction (including hypotension, nausea, vomiting, diaphoresis, and shivering) (FDA 2020a)
- Warnings/Precautions
    - Pharmacy will monitor labs daily prior to dispensing medication
    - If infusion reactions occur, discontinue administration and institute appropriate treatment if a clinically significant reaction and notify provider immediately
- Monitoring
    - CMP x1 at baseline and Daily x5
    - Signs and symptoms of infusion reaction
- Excretion: Urine-74% (majority as metabolites); Feces-18%
- IV Compatibilities: Unknown (Should only run with plain saline)

Nursing Education for Remdesivir

References

Johnston, K.S. (2020, December). Drug monograph: Remdesivir (Veklury-Gilead).

Gilead. (2020). Fact sheet for healthcare provider's emergency use authorization (EUA) of Remdesivir (GS-5734™). Retrieved from https://www.gilead.com/-/media/files/pdfs/remdesivir/eua-fact-sheet-for-hcps_01may2020.pdf?la=en&hash=B56F8C441364B7EDA15543F75E8EC88F

Gilead. (2020, October). Highlights of prescribing information: Veklury. Retrieved from https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf

Lexicomp. (2020). Remdesivir. Retrieved from http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6925182?searchUrl=%2Flco%2Faction%2Fsearch%3Bjsessionid%3DB8720165D9259F0270809342212547B0%3Forigin%3Dapi%26t%3Dglobalid%26q%3D869929%26nq%3Dtrue

Up to Date. (2020). Remdesivir (United States: Investigational agent; refer to Prescribing and Access Restrictions): Drug information. Retrieved from https://www.uptodate.com/contents/remdesivir-united-states-investigational-agent-refer-to-prescribing-and-access-restrictions-drug-information?search=remdesivir&source=panel_search_result&selectedTitle=1~17&usage_type=panel&kp_tab=drug_general&display_rank=1